WTWO, BNVI, CICS, ESYM, DARA, EREI Stocks to Watch for Wednesday, August 5th from OTCPicks.com

OTCPicks.com Stocks to Watch for Wednesday, August 5^th WTWO, BNVI, CICS, ESYM, DARA, EREI

Our Stocks to Watch tomorrow include W2 Energy Inc. (OTC: WTWO), Bionovo Inc. (Nasdaq: BNVI), Carbonics Capital Corp. (OTCBB: CICS), EcoSystem Corp. (OTCBB: ESYM), DARA BioSciences Inc. (Nasdaq: DARA) and Worldwide Food Services Inc. (OTC: EREI).

Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.

W2 ENERGY INCORPORATED (OTC: WTWO)

"Up 300.00% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/WTWO.php

W2 Energy Inc. is a growing, publicly traded company that develops renewable energy technologies and applies it to new generation power systems. Specifically, W2 Energy Inc.'s plasma assisted biomass-to-energy plants utilize state of the art technologies to produce green energy both fuel (sulfur free diesel) and electricity at the most efficient cost in capital investment and production per/barrel, per/Megawatt.

WTWO News:

August 4 - W2 Energy Inc. Completes Commercial Scale Algae Bioreactor

W2 Energy Inc. (OTC: WTWO), a developer of green energy, announced it has successfully completed a commercial scale algae bioreactor.

The Sunfilter bioreactor will be used to sequester any CO2 byproducts from the W2 Energy waste to energy processes well as the product can also be sold separately. Customers such as algae producers, biodiesel producers, labs, aquaculture companies, coal and petroleum plants are among the Sunfilter target market.

W2 Energy's Sunfilter is a low cost, low energy consuming bioreactor capable of being ganged together to fit any large scale need as well as be able to stand alone for small scale applications.

The algae for fuel market is quickly growing and the W2 Energy Sunfilter will fit the needs of many producers. Recently Exxon announced on CNN it was beginning to develop algae production for the use of fuel. W2 Energy is past the development stage and is now ready to market our products.

BIONOVO INCORPORATED (NASDAQ: BNVI)

"Up 45.00% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/BNVI.php 

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets.

BNVI News:

August 3 - Bionovo Presents Positive Results from Phase 1B Trial of Bezielle for Metastatic Breast Cancer

Bionovo Presents Positive Results from Phase 1B Trial of Bezielle for Metastatic Breast Cancer

Bionovo, Inc. (Nasdaq: BNVI) announced positive results from the Phase 1B clinical trial of Bezielle (formerly BZL101), their lead drug candidate for advanced breast cancer. In the trial, Bezielle showed an excellent safety and tolerability profile, and also showed promising indications of efficacy in a difficult-to-treat population.

The Phase 1B clinical trial was conducted at eight US clinical sites under the directorship of Dr. Charles Shapiro, Professor of Medicine and Director of Breast Oncology at Ohio State University. The primary objective of the study was to identify the maximum tolerated dose of Bezielle and to determine the safety, feasibility and preliminary efficacy of the Company's novel, oral, anticancer therapy. A total of twenty-seven women with metastatic breast cancer were enrolled to the Phase 1B trial.

To date, 48 women with advanced breast cancer have been successfully treated with Bezielle in two early clinical trials. In a previous Phase 1A study, Bezielle demonstrated very limited toxicity with a favorable tolerability profile and encouraging clinical activity among a cohort of patients with metastatic breast cancer who had been heavily pretreated with anticancer therapies. Results from this second Phase 1B study provide further support that Bezielle is safe and well-tolerated, with early signs of clinical efficacy.

Safety Analysis

In comparison to other oral cytotoxic agents, Bezielle was extremely safe and well tolerated. No drug-related deaths or serious adverse events occurred during the study, and 94% of all drug-related adverse events were classified as grade 1 and 2 side effects per the National Cancer Institute Common Terminology Criteria for Adverse Events. The most common adverse events associated with Bezielle were grade 1 and 2 gastrointestinal side effects, accounting for 56% of all drug-related adverse events.

Efficacy Analysis

Sixteen of the twenty-seven participants in the Phase 1B clinical trial were evaluable according to the Response Evaluation Criteria in Solid Tumors (RECIST). Of these sixteen evaluable women, five (31%) were stable on Bezielle for greater than 90 days and two (13%) were stable on Bezielle for greater than 180 days. Three patients (19%) on Bezielle had objective tumor regression, as evaluated by an independent radiology review.

Four patients discontinued from the study with stable disease, and of these four patients, one patient had objective tumor regression during 449 days of Bezielle treatment and continues to be stable off of study medication for a total of 600 days. A second patient who discontinued Bezielle treatment with stable disease continues to be stable for 832 days and has not started any new anticancer treatment. A third patient who discontinued with stable disease was stable for 591 days before evidence of progression. Further analyses on overall survival and progression-free survival will be performed.

Dose Escalation and Compliance

Overall compliance with study medication was excellent with 90% of prescribed doses taken. A maximum tolerated dose, as defined in study protocol, was never established despite dose escalation reaching a dose that was four times (40g/day) the previously evaluated Phase 1A dose.

"We are eager to advance Bezielle to Phase 2 clinical testing as the drug continues to have an improved safety profile over currently available chemotherapeutic agents, and shows encouraging clinical activity in a cohort of women who have been heavily pretreated for metastatic breast cancer," said Dr. Mary Tagliaferri, President and Chief Medical Officer, Bionovo.

"We are encouraged by the results of the Company's second Phase 1 trial in women with advanced breast cancer," said Isaac Cohen, Chairman and CEO of Bionovo. "Despite improvements in currently available breast cancer therapies, the five-year survival rate of women who develop metastatic disease is still only 27%. Many of these therapies cause women with advanced breast cancer additional discomfort through severe side effects resulting in a poor quality of life at the end of life. There are currently over 160,000 women in the United States living with advanced breast cancer who are eagerly awaiting an oral anticancer drug with minimal side effects that can extend life without profoundly diminishing their quality of life. We are aiming to improve the extract formulation so we can further improve on the gastrointestinal symptoms associated with Bezielle treatment. We believe Bezielle may be an important new anticancer agent because its biological selectivity allows it to kill cancer cells without affecting normal cells. This also leads to a dramatically lower side effect profile."

Bezielle

Bezielle is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. Bezielle targets diseased cells while leaving normal cells healthy and intact. Normal cells depend primarily on the citric acid cycle (>85%) and very little on glycolysis (<7%) for energy production. Cancer cells depend largely on glycolysis (>85%) for energy production. Bezielle induces greater production of reactive oxygen species in cancer cells. This results in high levels of DNA damage and the hyperactivation of PARP. The resulting depletion of NAD and ATP (PARP substrates), results in the inhibition of glycolysis, energetic collapse, and programmed necrosis.

There are currently no effective therapeutic cures for advanced breast cancer and treatment is primarily aimed at palliation of symptoms as well as improving overall survival. Over 192,000 women in the United States are diagnosed with breast cancer each year and breast cancer is the second leading cause of cancer death in women. Although survival after breast cancer treatment is improving, there are still over 40,000 deaths per year due to the disease in the Unites States alone.

CARBONICS CAPITAL CORPORATION (OTCBB: CICS)

"Up 50.00% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/CICS.php 

Carbonics Capital Corporation was founded to facilitate decarbonization in ways that cost-effectively capitalize on the evolving carbon markets.

CICS News:

July 27 - Carbonics Acquires Rights to Algae Bioreactor Technologies

Carbonics Capital Corporation (OTCBB: CICS) announced that it has entered into an exclusive license with GreenShift Corporation (OTCBB: GERS) for use of its algae bioreactor technologies in municipal and industrial applications excluding ethanol production.

GreenShift’s patented and patent-pending bioreactor technologies rely on thermophillic cyanobacteria (among other organisms) to consume carbon dioxide emissions and to produce carbon-neutral products. The organisms use the available carbon dioxide in the emissions and water to grow and give off oxygen and water vapor. The organisms also absorb nitrogen oxide and sulfur dioxide. All photosynthetic organisms need a supply of carbon dioxide, light, a growth media and water with nutrients to live and grow. GreenShift’s bioreactor technologies have the potential to reduce the costs and technical barriers to managing the flow resources into, through and out of the bioreactor in a compact and cost-efficient way as compared to other algae bioreactor technologies.

Carbonics’ wholly-owned subsidiary, Sustainable Systems, Inc., was awarded a $375,000 grant from the Montana Department of Commerce Research and Commercialization Technology program and is pursuing additional funding to apply toward this project to move this technology forward.

“While certain engineering hurdles must be overcome, we remain excited about this technology and its applications to manage carbon dioxide emissions while creating raw material for value added products,” stated Dr. Paul Miller, president and chief executive officer. In addition, Dr. Miller stated, “Our development team’s assessment of the algae production state of the art suggests that this is a practical closed system technology deployable on a large scale. What is unique about this technology is that we retain a high level of control of the environmental conditions within the system and we believe we can tailor the conditions for the production of biomass-derived chemicals and other products that can have commercial values greatly exceeding fuel.”

David Winsness, GreenShift’s Chief Technology Officer, added that “GreenShift is exclusively focused on the commercialization needs of its patent-pending extraction technologies. While we originally acquired our bioreactor technologies with a long-term goal of developing applications capable of integrating into corn ethanol plants, these technologies have many other applications. The Carbonics team has the ability to evaluate and develop those applications, and to manage the continued evolution of our bioreactor technologies.”

Under the terms of the license agreement, Carbonics will pay GreenShift ten percent of the pre-tax net income derived from the use of the technology or derived from the sale, sublicense or lease of technology related equipment. In addition, while GreenShift shall retain ownership of all improvements that Carbonics may develop, and the right to use any such improvements in GreenShift’s ethanol applications, Carbonics shall retain the right to use those improvements under the license agreement.

ECOSYSTEM CORPORATION (OTCBB: ESYM)

"Up 35.48% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/ESYM.php 

EcoSystem’s ambition is to become a leading low-cost and low-carbon producer of renewable fuels by acquiring and upgrading existing corn ethanol facilities with technologies designed to increase the yield and to reduce the energy consumption and carbon intensity of refining fuel out of corn.

ESYM News:

July 30 - EcoSystem Executes Agreement for $76 Million in Equity Financing

EcoSystem Corporation (OTCBB: ESYM) announced its execution of agreements for the sale of EcoSystem preferred stock and warrants to purchase common stock to five investment funds for $76 million.

Funding under the agreements is expected to occur prior to August 5, 2009 upon the satisfaction by EcoSystem of pre-funding conditions. The funds will be held in a restricted EcoSystem account and will be available for use according to the use of proceeds schedule and other conditions specified in the agreements.

EcoSystem will use the investment proceeds to acquire distressed ethanol production facilities, to acquire other strategically-compatible assets, and to develop and integrate EcoSystem’s Cellulosic Corn™ technologies into EcoSystem’s planned ethanol production facilities.

EcoSystem’s goal is to achieve an annualized renewable fuel production rate of 500 million gallons per year within three years, and to demonstrate market leadership by using its technologies to refine more fuel out of corn for less cost on reduced energy consumption and carbon emitted.

Detailed information regarding this investment is available online at www.eco-system.com in EcoSystem’s July 30, 2009 Form 8K.

Cellulosic Corn™

The corn ethanol industry contributed over $65 billion to the GDP by offsetting 7% of America's fossil fuel needs in 2008. EcoSystem intends to prove that corn has much more to add.

EcoSystem’s view is that the established first generation corn ethanol infrastructure is the only practical pathway in North America to cost-effectively increase the production and use of carbon-neutral biofuels on globally-meaningful scales. To accomplish this in a competitive and environmentally superior way, the installed base of first generation corn ethanol facilities will need to evolve to achieve significantly improved production efficiencies. EcoSystem intends to do just that, and to become a leading low cost and low carbon producer of renewable fuels by leveraging its technology portfolio to acquire and upgrade corn ethanol facilities into increased financial and environmental sustainability while facilitating the convergence of cellulosic and corn ethanol.

EcoSystem’s portfolio of patented and patent-pending Cellulosic Corn™ technologies are designed to achieve the following key goals:

* Increase the net energy balance of biofuel derived from corn;

* Increase profitability of corn ethanol;

* Decrease amount of petroleum burned to make corn derived biofuel;

* Increase the nutritional content of corn ethanol co-products;

* Reduce, reuse and recycle the carbon emissions of corn ethanol production;

* Diversify the biomass mix accepted and produced by traditional corn ethanol facilities;

* Decrease the commodity and financial risk profile of corn ethanol;

* Standardize corn-friendly cellulosic technology by building on the existing corn ethanol complex; and,

* Enhance the competitive positioning of corn ethanol in the domestic and global markets.

DARA BIOSCIENCES INCORPORATED (NASDAQ: DARA)

"Up 40.74% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/DARA.php

DARA BioSciences™ Inc. ("DARA") is a Raleigh, North Carolina based development-stage pharmaceutical company that acquires promising therapeutic small molecules and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND's (Investigational New Drug) Applications from the US FDA. One of these drug candidates KRN5500 has successfully completed a Phase 2a clinical trial treating cancer patients for neuropathic pain. It has a portfolio of drug candidates for neuropathic pain, type 2 diabetes, and psoriasis.

DARA News:

August 4 - DARA BioSciences, Inc. and America Stem Cell, Inc. Collaborate On Stem Cell Research

DARA BioSciences, Inc. (Nasdaq: DARA) announced that the Company is collaborating with America Stem Cell ("ASC") to expand on observations from recent preclinical studies showing that dipeptidylpeptidase (DPPIV) inhibitors improve the efficiency of hematopoietic stem cell (HSC) transplants. HSC transplants are used as a therapeutic approach for many malignant and non-malignant hematological disorders.

ASC will expand on these previous observations with preclinical studies utilizing potent and selective DPPIV inhibitors obtained from DARA BioSciences. The goal of this collaboration is to accelerate the translation of this approach to the clinic for the benefit of many patients in need of a HSC transplant.

ABOUT AMERICA STEM CELL, INC.

America Stem Cell, Inc. ("ASC") is a privately held biotechnology company based in Carlsbad, CA, and is dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cells. The Company possesses two key technology platforms – ASC-101 and ASC-201 – that are designed to improve the engraftment of stem cells to target organs and increase their therapeutic potential.

WORLDWIDE FOOD SERVICES INCORPORATED (OTC: EREI)

"Up 29.41% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/EREI.php

Worldwide Food Services has established an international marketing and distribution system for food and beverage products in a global economy. The company was formerly known as Eagle Rock Enterprises, Inc.

EREI News:

August 3 - Worldwide Food Services Expands Product Line

Worldwide Food Services Incorporated (OTC: EREI) (“WWFS”), in expanding its scope of supply, has secured a supplier of cement who not only owns the cement but controls the shipping. This will afford the Company to quote CIF (cost, insurance, and freight) delivered to the customer. WWFS is currently negotiating with companies in Dubai and North Africa for a renewable annual supply.

OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.

Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

Disclosure: OTCPicks.com has not been compensated by any of the companies covered in this release.